ADC Therapeutics
ADCT
52 hedge funds and large institutions have $921M invested in ADC Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
27% more funds holding
Funds holding: 41 → 52 (+11)
6.31% more ownership
Funds ownership: 30.48% → 36.79% (+6.3%)
8% less capital invested
Capital invested by funds: $1B → $921M (-$79.6M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $336K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$105M |
| 2 |
JP Morgan Chase
New York
|
+$40.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$35.8M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$18.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$8.66M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$8.2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.77M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.39M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$380K |
ADCT Hedge Fund Activity: Q3 2020 in Review
52 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2020, worth a combined $921M — down 8% from $1B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADCT positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $105M. The largest seller was Deerfield Management, cutting an estimated $8.66M.
- 52 institutional investors held ADC Therapeutics (ADCT) as of Q3 2020, up from 41 in Q2 2020.
- Funds reported $921M of ADC Therapeutics stock for Q3 2020, down 8% quarter-over-quarter.
- 16 funds opened new ADC Therapeutics positions in Q3 2020 and 5 closed out, a net change of +11 holders.
- The largest ADC Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $105M added.
- The largest ADC Therapeutics seller in Q3 2020 was Deerfield Management, an estimated $8.66M sold.
Based on aggregated 13F filings for Q3 2020.